BindingDB logo
myBDB logout

76 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
27838170 2 An evaluation of central penetration from a peripherally administered oxytocin receptor selective antagonist in nonhuman primates.EBI Emory University
11992786 42 Identification of potent and selective oxytocin antagonists. Part 1: indole and benzofuran derivatives.EBI GlaxoSmithKline
11392542 25 Structure-activity relationship investigations of a potent and selective benzodiazepine oxytocin antagonist.EBI GlaxoSmithKline
27297999 37 Systematic N-methylation of oxytocin: Impact on pharmacology and intramolecular hydrogen bonding network.EBI Pfizer Inc
26741855 65 Flexible analogues of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin 1a receptors.EBI The University of Sydney
25654260 49 Discovery of highly selective brain-penetrant vasopressin 1a antagonists for the potential treatment of autism via a chemogenomic and scaffold hopping approach.EBI F. Hoffmann-La Roche Inc
25642985 45 Selective nonpeptidic fluorescent ligands for oxytocin receptor: design, synthesis, and application to time-resolved FRET binding assay.EBI University of Strasburg
24874785 333 New, potent, and selective peptidic oxytocin receptor agonists.EBI Ferring Research Institute Inc.
25408829 10 Pyrazolsulfonamide agonists of oxytocin receptor.EBI Dart Neuroscience LLC
16250654 41 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 2. Synthesis, chirality, and pharmacokinetics.EBI GlaxoSmithKline
23978650 2 Investigation of an F-18 oxytocin receptor selective ligand via PET imaging.EBI Emory University
23270988 4 Carbon-11 N-methyl alkylation of L-368,899 and in vivo PET imaging investigations for neural oxytocin receptors.EBI Yerkes National Primate Research Center
21700453 56 Optimisation of pharmacokinetic properties to afford an orally bioavailable and selective V1A receptor antagonist.EBI MSD
21146408 53 The characterization of a novel V1b antagonist lead series.EBI GlaxoSmithKline
20674355 58 Pyrrolo[1,2-a]pyrazine and pyrazolo[1,5-a]pyrazine: novel, potent, and selective series of Vasopressin 1b receptor antagonists.EBI GlaxoSmithKline
19081251 38 Discovery and optimisation of a potent and selective tertiary sulfonamide oxytocin antagonist.EBI GlaxoSmithKline
22984902 59 Selective fluorescent nonpeptidic antagonists for vasopressin V2 GPCR: application to ligand screening and oligomerization assays.EBI University of Strasburg
22239250 59 Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency.EBI GlaxoSmithKline
22425346 28 Synthesis and evaluation of C-11, F-18 and I-125 small molecule radioligands for detecting oxytocin receptors.EBI Emory University
20104850 48 Subtlety of the structure-affinity and structure-efficacy relationships around a nonpeptide oxytocin receptor agonist.EBI University of Strasburg
19800231 92 Tetrahydroquinoline sulfonamides as vasopressin 1b receptor antagonists.EBI Schering-Plough Research Institute
19095447 28 Discovery and optimization of highly ligand-efficient oxytocin receptor antagonists using structure-based drug design.EBI GlaxoSmithKline
18032036 17 The discovery of GSK221149A: a potent and selective oxytocin antagonist.EBI GlaxoSmithKline
17850055 18 Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands.EBI Institute Genomics Functional (IGF)
17300166 88 Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.EBI University of Montpellier
16302826 129 Discovery and development of a new class of potent, selective, orally active oxytocin receptor antagonists.EBI Serono Pharmaceutical Research Institute
15084136 96 Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4.EBI Medical College of Ohio
13678399 54 Peptide science: exploring the use of chemical principles and interdisciplinary collaboration for understanding life processes.EBI University of Arizona
12036367 46 Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors.EBI University of Montpellier
7507528 23 Enhanced selectivity of oxytocin antagonists containing sarcosine in position 7.EBI Max-Planck-Institut f£r Biophysik
1331448 101 Development of a novel class of cyclic hexapeptide oxytocin antagonists based on a natural product.EBI Merck Research Laboratories
10201826 24 Synthesis of oxytocin antagonists containing conformationally constrained amino acids in position 2.EBI Albert Szent-Gy£rgyi Medical University
21688787 295 New, potent, selective, and short-acting peptidic V1a receptor agonists.EBI Ferring Research Institute Inc.
21605973 69 Potent and selective oxindole-based vasopressin 1b receptor antagonists with improved pharmacokinetic properties.EBI Abbott Laboratories
21601454 26 Identification and optimisation of novel sulfonamide, selective vasopressin V1B receptor antagonists.EBI MSD
21428295 43 Design, synthesis, and pharmacological characterization of fluorescent peptides for imaging human V1b vasopressin or oxytocin receptors.EBI University of Montpellier
21353540 55 Synthesis and SAR studies of novel 2-(4-oxo-2-aryl-quinazolin-3(4H)-yl)acetamide vasopressin V1b receptor antagonists.EBI MSD
21117646 25 Modulating oxytocin activity and plasma stability by disulfide bond engineering.EBI The University of Queensland
20550119 96 Oral oxytocin antagonists.EBI DrugMolDesign
20719508 26 Identification and optimization of novel 2-(4-oxo-2-aryl-quinazolin-3(4H)-yl)acetamide vasopressin V3 (V1b) receptor antagonists.EBI Ligand Pharmaceuticals Inc
20189387 46 Identification of amide bioisosteres of triazole oxytocin antagonists.EBI Pfizer Inc
20172721 21 Identification of a urea bioisostere of a triazole oxytocin antagonist.EBI Pfizer Inc
19963374 68 Triazole oxytocin antagonists: Identification of an aryloxyazetidine replacement for a biaryl substituent.EBI Pfizer Inc
19376698 16 Aryloxypyrazines as highly selective antagonists of Oxytocin.EBI Pfizer Inc
19053774 56 New benzylureas as a novel series of potent, nonpeptidic vasopressin V2 receptor agonists.EBI Vantia Ltd
18778939 23 Triazole oxytocin antagonists: identification of aryl ether replacements for a biaryl substituent.EBI Pfizer Inc
18639455 43 Design and optimization of potent, selective antagonists of Oxytocin.EBI Pfizer Inc
17855087 19 Identification and synthesis of major metabolites of Vasopressin V2-receptor agonist WAY-151932, and antagonist, Lixivaptan.EBI Wyeth Research
17316912 63 Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7.EBI University of Patras
16821776 13 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency.EBI Cardiovascular and Urogenital Centre of Excellence for Drug Discovery
15357997 22 Non-peptide oxytocin agonists.EBI Ferring Research Ltd
11992787 37 Identification of potent and selective oxytocin antagonists. Part 2: further investigation of benzofuran derivatives.EBI GlaxoSmithKline
11520211 7 Design, synthesis and pharmacological characterization of a potent radioiodinated and photoactivatable peptidic oxytocin antagonist.EBI University of Montpellier
11392541 2 Identification of a potent and selective oxytocin antagonist, from screening a fully encoded differential release combinatorial chemical library.EBI GlaxoSmithKline
10522694 4 The synthesis of a new class of oxytocin antagonists.EBI Ferring Research Institute Inc.
10340620 30 Nonpeptide oxytocin antagonists: analogs of L-371,257 with improved potency.EBI Merck Research Laboratories
10197974 22 Fluorescent pseudo-peptide linear vasopressin antagonists: design, synthesis, and applications.EBI University of Montpellier
9873680 21 Nonpeptide oxytocin antagonists: potent, orally bioavailable analogs of L-371,257 containing a 1-R-(pyridyl)ethyl ether terminus.EBI Merck Research Laboratories
9703459 5 Peptidomimetic growth hormone secretagogues. Design considerations and therapeutic potential.EBI Merck Research Laboratories
9622556 63 Development of orally active oxytocin antagonists: studies on 1-(1-[4-[1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]-2- methoxybenzoyl]piperidin-4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and related pyridines.EBI Merck Research Laboratories
8258821 491 Nanomolar-affinity, non-peptide oxytocin receptor antagonists.EBI Merck Research Laboratories
7473590 37 1-(1-[4-[(N-acetyl-4-piperidinyl)oxy]-2-methoxybenzoyl]piperidin-4- yl)-4H-3,1-benzoxazin-2(1H)-one (L-371,257): a new, orally bioavailable, non-peptide oxytocin antagonist.EBI Merck Research Laboratories
30199637 172 LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism.EBI UMR7200 CNRS/Universit£ de Strasbourg
30015488 44 Discovery, Synthesis, Pharmacological Profiling, and Biological Characterization of Brintonamides A-E, Novel Dual Protease and GPCR Modulators from a Marine Cyanobacterium.EBI University of Florida
29126725 95 Conformationally rigid derivatives of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin-1a receptors.EBI The University of Sydney
28505537 35 Investigation of pyrazolo-sulfonamides as putative small molecule oxytocin receptor agonists.EBI The University of Sydney
29602673 49 Building bridges for highly selective, potent and stable oxytocin and vasopressin analogs.EBI Imperial College
29039668 4 Targets for Drug Therapy for Autism Spectrum Disorder: Challenges and Future Directions.EBI Universit£ degli Studi di Bari Aldo Moro
28438540 207 Potent and selective oxytocin receptor agonists without disulfide bridges.EBI Takeda Pharmaceutical Co., Ltd
25035921 44 Pyrazolopyrimidines Establish MurC as a Vulnerable Target in Pseudomonas aeruginosa and Escherichia coli.BDB AstraZeneca India Pvt. Ltd.